New biosimilar aims to offer cheaper psoriasis treatment
NCT ID NCT07254325
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 1 study compares a new biosimilar drug, CMAB015, to the approved psoriasis treatment Cosentyx (secukinumab). The trial involves 114 healthy Chinese men who receive a single injection. Researchers will measure how the drug moves through the body, its safety, and whether the immune system reacts to it. This is an early step to see if the biosimilar is similar enough to Cosentyx to move into patient testing.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Secukinumab (biosimilar CMAB015)
What this could lead to
If successful, this could lead to a more affordable version of Cosentyx for psoriasis, potentially lowering treatment costs.
What could go wrong
This is an early Phase 1 trial in healthy volunteers, not patients. It only tests safety and drug levels, not whether it works for psoriasis. The biosimilar may not perform the same as the original drug.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSORIASIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shanghai Jiaotong University School of Medicine
Shanghai, China